Cardurion Pharmaceuticals, Inc. ("Cardurion"), a clinical-stage biotechnology company discovering and developing new ...

Truist Financial analyst Srikripa Devarakonda maintained a Buy rating on Biogen (BIIB – Research Report) yesterday and set a price target of ...

Truist analyst Srikripa Devarakonda lowered the firm’s price target on Biogen (BIIB) to $220 from $302 and keeps a Buy rating on the shares as ...

Shares of Solid Biosciences (NASDAQ:SLDB) jumped 11% post-market after the company said the FDA had cleared an ...

Day One Biopharmaceuticals focuses on pediatric cancer treatments. Read more about the biotech's therapies and its prospects ...

RBC Capital lowered the firm’s price target on Biogen (BIIB) to $231 from $260 and keeps an Outperform rating on the shares as part of a ...

Article analyzes Amgen's strong clinical progress and financials, recommending caution due to valuation and technical ...

Analysis of Biogen's stock performance in 2024, focusing on sales struggles, financial health, and valuation. Read more here.

In order from steepest decline to narrowest, the five unloved were Intel(NASDAQ: INTC), MongoDB(NASDAQ: MDB), Biogen(NASDAQ: BIIB), DexCom(NASDAQ: DXCM), and Microchip Technology(NASDAQ: MCHP).

William Blair has initiated coverage on Denali Therapeutics Inc (NASDAQ:DNLI), a company focused on developing drugs for ...

The end-of-year decline on US stock markets continued into 2025, with all three Wall Street benchmarks registering yet more ...

Biogen (BIIB) stock slipped as Piper Sandler downgraded the company to neutral from overweight, citing challenges in Alzheimer's drug market. Read more here.